1. FOR IMMEDIATE RELEASE
CONTACT:
Kelly Sladek
SCORR Marketing
308.237.5567
Kelly@scorrmarketing.com
KCAS Announces Rebranding Completion and KansasBio Sponsorship
(Shawnee, Kansas; April 20, 2010) – KCAS, LLC, a bioanalytical laboratory specializing in
high-quality research and analytical services for pharmaceutical, biotech, animal health and
medical device companies, is pleased to announce the completion of its rebranding,
establishing itself as KCAS, and the honor of being in the Kansas Bioscience Organization’s
(KansasBio) All-Star Lineup and a founding member of the region’s National Drug Development
Accelerator (NDDA) team.
Twelve years after being acquired by AAIPharma, Kansas City Analytical Services has
re-established itself as KCAS, LLC. With the capacity to analyze over 250,000 samples per
year, KCAS provides clients with best-in-class bioanalytical services, including method
development, validation and high-throughput sample analysis on biological samples for
preclinical and clinical studies.
“Building on our 30-plus-year history and uncompromised attention to quality, we
emphasize that our mission at KCAS is to produce reliable, high-quality results for small
molecule, large molecule and biomarker analysis. We have been very pleased with the positive
response from our core clients, which shows that this move is a welcome change and will be
quite successful,” stated President and Scientific Director of KCAS Dari Dadgar, Ph.D.
-more-
2. KansasBio created the NDDA for companies like KCAS in 2008. The NDDA highlights
the breadth of experience and depth of knowledge in the greater Kansas City and surrounding
areas. KCAS has become an integral part of drug development by providing discovery,
preclinical and clinical services for the national and global biotech and pharmaceutical
community. In an effort to show just how important the area is for drug development
companies, KCAS has teamed up with KansasBio for the 2010 BIO International Convention as
an Industry Sponsor in their All-Star Lineup.
“We are enthusiastic about growing this business in a strategic and thoughtful manner.
We have carved out niche markets, such as alkaline hematin, and are expanding our large
molecule capabilities. Our customers should expect to see the same scientific expertise, rapid
turnaround and flexibility as previous years, as well as some exciting news about us in 2010,"
stated Vice President of Operations at KCAS Michael Lanman.
In addition to the small molecule and large molecule bioanalytical services, KCAS has
established a proprietary, validated method for quantitative measurement of menstrual blood
loss (alkaline hematin) in support of women’s health programs. This method is currently
registered with the FDA, making KCAS a recognized leader in this field.
About KCAS, LLC
KCAS provides a full range of high-quality analytical services to pharmaceutical companies of all sizes. For more than
30 years, KCAS has provided bioanalytical services to pharmaceutical, biotech animal health and medical device
companies. Delivering responsive, reliable and personalized results, KCAS boosts clients’ bottom lines by enabling
them to get drugs to market more quickly and effectively. For more information about KCAS, visit www.kcasbio.com.
###
